SG Americas Securities LLC bought a new stake in shares of Edge Therapeutics Inc (NASDAQ:EDGE) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 11,001 shares of the biotechnology company’s stock, valued at approximately $103,000.
Other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in shares of Edge Therapeutics by 223.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 379,075 shares of the biotechnology company’s stock valued at $4,063,000 after buying an additional 261,850 shares during the period. Sphera Funds Management LTD. increased its holdings in Edge Therapeutics by 122.5% during the 3rd quarter. Sphera Funds Management LTD. now owns 333,737 shares of the biotechnology company’s stock worth $3,581,000 after purchasing an additional 183,737 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in Edge Therapeutics during the 2nd quarter worth approximately $374,000. Teachers Advisors LLC increased its holdings in Edge Therapeutics by 21.1% during the 2nd quarter. Teachers Advisors LLC now owns 34,329 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 5,976 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Edge Therapeutics by 44.4% during the 3rd quarter. Wells Fargo & Company MN now owns 17,249 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 5,307 shares during the last quarter. Institutional investors and hedge funds own 48.89% of the company’s stock.
In other news, CEO Brian A. Leuthner sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $13.14, for a total value of $32,850.00. Following the completion of the sale, the chief executive officer now directly owns 82,736 shares in the company, valued at approximately $1,087,151.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider R. Loch Macdonald sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $13.75, for a total value of $68,750.00. Following the completion of the sale, the insider now owns 590,602 shares of the company’s stock, valued at $8,120,777.50. The disclosure for this sale can be found here. Insiders sold a total of 17,500 shares of company stock valued at $225,400 over the last quarter. Company insiders own 36.19% of the company’s stock.
Several equities research analysts have issued reports on the company. BidaskClub upgraded Edge Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 7th. Credit Suisse Group restated an “outperform” rating and set a $17.00 price objective on shares of Edge Therapeutics in a report on Thursday, January 18th. Finally, Zacks Investment Research downgraded Edge Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd.
Shares of Edge Therapeutics stock traded down $0.31 during midday trading on Monday, hitting $16.60. The stock had a trading volume of 75,405 shares, compared to its average volume of 164,610. Edge Therapeutics Inc has a 1-year low of $7.30 and a 1-year high of $17.77. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.28.
Edge Therapeutics (NASDAQ:EDGE) last issued its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.02).
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.